Gil M. Labrucherie Acquires 5,000 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 5,000 shares of the stock in a transaction dated Friday, February 21st. The shares were purchased at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,000 shares in the company, valued at approximately $175,500. This trade represents a 20.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Stock Down 1.5 %

Shares of NASDAQ:SEPN opened at $5.80 on Monday. The firm has a 50-day simple moving average of $17.78. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SEPN. Tower Research Capital LLC TRC bought a new stake in shares of Septerna during the fourth quarter worth $25,000. New York State Common Retirement Fund bought a new stake in Septerna during the 4th quarter valued at about $32,000. Legal & General Group Plc purchased a new stake in Septerna in the 4th quarter valued at about $42,000. Summit Investment Advisors Inc. bought a new position in Septerna in the 4th quarter worth about $45,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Septerna during the fourth quarter worth approximately $52,000.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. initiated coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock. Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $43.00 to $14.00 in a research note on Tuesday, February 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th. Finally, TD Cowen began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set a “buy” rating on the stock.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.